Cargando…

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)

PURPOSE: INVICOST, a medico-economic analysis, compared costs of managing treatment-naive patients with diabetic macular edema (DME) receiving intravitreal injections (IVIs) of aflibercept (AFL), dexamethasone implant (DXI) or ranibizumab (RAN) over 1 year. METHODS: Healthcare resource use and assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gascon, Pierre, Borget, Isabelle, Comet, Alban, Carton, Laurence, Matonti, Frédéric, Dupont-Benjamin, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109236/
https://www.ncbi.nlm.nih.gov/pubmed/34284605
http://dx.doi.org/10.1177/11206721211033480
_version_ 1784708862300913664
author Gascon, Pierre
Borget, Isabelle
Comet, Alban
Carton, Laurence
Matonti, Frédéric
Dupont-Benjamin, Laure
author_facet Gascon, Pierre
Borget, Isabelle
Comet, Alban
Carton, Laurence
Matonti, Frédéric
Dupont-Benjamin, Laure
author_sort Gascon, Pierre
collection PubMed
description PURPOSE: INVICOST, a medico-economic analysis, compared costs of managing treatment-naive patients with diabetic macular edema (DME) receiving intravitreal injections (IVIs) of aflibercept (AFL), dexamethasone implant (DXI) or ranibizumab (RAN) over 1 year. METHODS: Healthcare resource use and associated costs were estimated using individual patient data from INVICTUS, a prospective, open-label, monocentric study. Healthcare costs comprised direct medical costs such as drug acquisition and administration, consultations and ophthalmological procedures. Costs were assessed from the French National Health Insurance perspective using published national tariffs expressed in 2019 euros. RESULTS: Of the 60 treated eyes, 48 had no treatment switch; 14 received AFL, 19 received DXI and 15 received RAN. AFL-treated eyes received an average of 6.5 IVIs, DXI-treated patients received 2 IVIs and RAN-treated received 6.8 IVIs. All treated eyes received an initial prescription for adjunctive ocular medications and 349 follow-up procedures were performed including an average of 3.9 optical coherence tomography and 3.2 retinography procedures per eye. Average total direct cost of per-eye treatment was €4516 (€1128–€8257). Average cost was €5782 for eyes treated with AFL, €2779 with DXI and €5536 with RAN. Drug therapy was the cost driver: €4394 (76%) for AFL, €1915 for DXI (69%) and €4268 (77%) for RAN. CONCLUSION: The difference in total treatment cost is largely explained by the significantly lower frequency of IVI and annual cost of therapy with DXI, compared with AFL and RAN. INVICOST is the first study comparing treatment costs with AFL, DXI and RAN in France in current clinical practice.
format Online
Article
Text
id pubmed-9109236
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91092362022-05-17 Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study) Gascon, Pierre Borget, Isabelle Comet, Alban Carton, Laurence Matonti, Frédéric Dupont-Benjamin, Laure Eur J Ophthalmol Original Research Articles PURPOSE: INVICOST, a medico-economic analysis, compared costs of managing treatment-naive patients with diabetic macular edema (DME) receiving intravitreal injections (IVIs) of aflibercept (AFL), dexamethasone implant (DXI) or ranibizumab (RAN) over 1 year. METHODS: Healthcare resource use and associated costs were estimated using individual patient data from INVICTUS, a prospective, open-label, monocentric study. Healthcare costs comprised direct medical costs such as drug acquisition and administration, consultations and ophthalmological procedures. Costs were assessed from the French National Health Insurance perspective using published national tariffs expressed in 2019 euros. RESULTS: Of the 60 treated eyes, 48 had no treatment switch; 14 received AFL, 19 received DXI and 15 received RAN. AFL-treated eyes received an average of 6.5 IVIs, DXI-treated patients received 2 IVIs and RAN-treated received 6.8 IVIs. All treated eyes received an initial prescription for adjunctive ocular medications and 349 follow-up procedures were performed including an average of 3.9 optical coherence tomography and 3.2 retinography procedures per eye. Average total direct cost of per-eye treatment was €4516 (€1128–€8257). Average cost was €5782 for eyes treated with AFL, €2779 with DXI and €5536 with RAN. Drug therapy was the cost driver: €4394 (76%) for AFL, €1915 for DXI (69%) and €4268 (77%) for RAN. CONCLUSION: The difference in total treatment cost is largely explained by the significantly lower frequency of IVI and annual cost of therapy with DXI, compared with AFL and RAN. INVICOST is the first study comparing treatment costs with AFL, DXI and RAN in France in current clinical practice. SAGE Publications 2021-07-20 2022-05 /pmc/articles/PMC9109236/ /pubmed/34284605 http://dx.doi.org/10.1177/11206721211033480 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Articles
Gascon, Pierre
Borget, Isabelle
Comet, Alban
Carton, Laurence
Matonti, Frédéric
Dupont-Benjamin, Laure
Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
title Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
title_full Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
title_fullStr Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
title_full_unstemmed Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
title_short Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
title_sort costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in france (invicost study)
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109236/
https://www.ncbi.nlm.nih.gov/pubmed/34284605
http://dx.doi.org/10.1177/11206721211033480
work_keys_str_mv AT gasconpierre costscomparisonoftreatingdiabeticmacularedemawithafliberceptranibizumabordexamethasoneat1yearinfranceinvicoststudy
AT borgetisabelle costscomparisonoftreatingdiabeticmacularedemawithafliberceptranibizumabordexamethasoneat1yearinfranceinvicoststudy
AT cometalban costscomparisonoftreatingdiabeticmacularedemawithafliberceptranibizumabordexamethasoneat1yearinfranceinvicoststudy
AT cartonlaurence costscomparisonoftreatingdiabeticmacularedemawithafliberceptranibizumabordexamethasoneat1yearinfranceinvicoststudy
AT matontifrederic costscomparisonoftreatingdiabeticmacularedemawithafliberceptranibizumabordexamethasoneat1yearinfranceinvicoststudy
AT dupontbenjaminlaure costscomparisonoftreatingdiabeticmacularedemawithafliberceptranibizumabordexamethasoneat1yearinfranceinvicoststudy